Patents by Inventor John E. Hearst
John E. Hearst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7927606Abstract: Free-living microbes are provided in which the nucleic acid has been modified so that the microbe is attenuated for proliferation and/or which comprise genetic mutations that attenuate the ability of the microbe to repair its nucleic acid. Methods of using the modified microbes for the loading, activation, and/or maturation of antigen-presenting cells are also provided. Vaccine compositions comprising the modified microbes and/or the antigen-presenting cells and methods of using the vaccines are also provided. The microbes may be further modified to include heterologous antigens, such as tumor antigens or infectious disease antigens, for use as a vaccine against cancer or infectious diseases.Type: GrantFiled: August 11, 2006Date of Patent: April 19, 2011Assignee: Aduro BiotechInventors: Thomas W. Dubensky, Jr., Dirk G. Brockstedt, Keith S. Bahjat, John E. Hearst, David N. Cook, William S. Luckett, Jr.
-
Patent number: 7833775Abstract: Free-living microbes are provided in which the nucleic acid has been modified so that the microbe is attenuated for proliferation and/or which comprise genetic mutations that attenuate the ability of the microbe to repair its nucleic acid. Methods of using the modified microbes for the loading, activation, and/or maturation of antigen-presenting cells are also provided. Vaccine compositions comprising the modified microbes and/or the antigen-presenting cells and methods of using the vaccines are also provided. The microbes may be further modified to include heterologous antigens, such as tumor antigens or infectious disease antigens, for use as a vaccine against cancer or infectious diseases.Type: GrantFiled: February 6, 2004Date of Patent: November 16, 2010Assignee: Aduro BioTechInventors: Thomas W. Dubensky, Jr., Dirk G. Brockstedt, John E. Hearst, David N. Cook
-
Patent number: 7695725Abstract: Free-living microbes are provided in which the nucleic acid has been modified so that the microbe is attenuated for proliferation and/or which comprise genetic mutations that attenuate the ability of the microbe to repair its nucleic acid. Methods of using the modified microbes for the loading, activation, and/or maturation of antigen-presenting cells are also provided. Vaccine compositions comprising the modified microbes and/or the antigen-presenting cells and methods of using the vaccines are also provided. The microbes may be further modified to include heterologous antigens, such as tumor antigens or infectious disease antigens, for use as a vaccine against cancer or infectious diseases.Type: GrantFiled: June 30, 2004Date of Patent: April 13, 2010Assignee: Aduro BiotechInventors: Thomas W. Dubensky, Jr., Dirk G. Brockstedt, John E. Hearst, David N. Cook, William S. Luckett, Jr.
-
Publication number: 20100068230Abstract: Free-living microbes are provided in which the nucleic acid has been modified so that the microbe is attenuated for proliferation and/or which comprise genetic mutations that attenuate the ability of the microbe to repair its nucleic acid. Methods of using the modified microbes for the loading, activation, and/or maturation of antigen-presenting cells are also provided. Vaccine compositions comprising the modified microbes and/or the antigen-presenting cells and methods of using the vaccines are also provided. The microbes may be further modified to include heterologous antigens, such as tumor antigens or infectious disease antigens, for use as a vaccine against cancer or infectious diseases.Type: ApplicationFiled: June 30, 2004Publication date: March 18, 2010Inventors: Thomas W. Dubensky, JR., Dirk G. Brockstedt, John E. Hearst, David N. Cook, William S. Luckett, JR.
-
Publication number: 20080248066Abstract: Free-living microbes are provided in which the nucleic acid has been modified so that the microbe is attenuated for proliferation and/or which comprise genetic mutations that attenuate the ability of the microbe to repair its nucleic acid. Methods of using the modified microbes for the loading, activation, and/or maturation of antigen-presenting cells are also provided. Vaccine compositions comprising the modified microbes and/or the antigen-presenting cells and methods of using the vaccines are also provided. The microbes may be further modified to include heterologous antigens, such as tumor antigens or infectious disease antigens, for use as a vaccine against cancer or infectious diseases.Type: ApplicationFiled: August 11, 2006Publication date: October 9, 2008Applicant: Cerus CorporationInventors: Thomas W. Dubensky, Dirk G. Brockstedt, Keith S. Bahjat, John E. Hearst, David N. Cook, William S. Luckett
-
Publication number: 20040197343Abstract: Free-living microbes are provided in which the nucleic acid has been modified so that the microbe is attenuated for proliferation and/or which comprise genetic mutations that attenuate the ability of the microbe to repair its nucleic acid. Methods of using the modified microbes for the loading, activation, and/or maturation of antigen-presenting cells are also provided. Vaccine compositions comprising the modified microbes and/or the antigen-presenting cells and methods of using the vaccines are also provided. The microbes may be further modified to include heterologous antigens, such as tumor antigens or infectious disease antigens, for use as a vaccine against cancer or infectious diseases.Type: ApplicationFiled: February 6, 2004Publication date: October 7, 2004Inventors: Thomas W. Dubensky, Dirk G. Brockstedt, Keith Bahjat, John E. Hearst, David Cook
-
Publication number: 20010036948Abstract: The present invention provides methods and compositions for inhibiting the proliferation of smooth muscle cells at a site of vascular injury. The methods include intravascular administration of a reactive compound to the site of injury, without the requirement for activation or sustained release of the compound.Type: ApplicationFiled: June 11, 2001Publication date: November 1, 2001Inventors: John E. Hearst, William M. Greenman, Susan Wollowitz, Ryan D. Alfonso
-
Patent number: 6281225Abstract: The present invention provides methods for inhibiting restenosis at a site of vascular recanalization. The methods include intravascular administration of a reactive acridine compound to the site of injury, without the requirement for activation or sustained release of the compound.Type: GrantFiled: June 10, 1999Date of Patent: August 28, 2001Assignee: Cerus CorporationInventors: John E. Hearst, William M. Greenman, Susan Wollowitz, Ryan D. Alfonso
-
Patent number: 5854967Abstract: A device comprising a light source, a sample holder and a temperature control chamber. The sample holder supports the vessels in a fixed relationship relative to the light source. The temperature control chamber surrounds the sample holder and vessels, so that a temperature control fluid may be passed around the sample vessels effectively maintaining the temperature of the sample vessels within a desired temperature range.Type: GrantFiled: February 25, 1997Date of Patent: December 29, 1998Assignee: Cerus CorporationInventors: David P. Hearst, George D. Cimino, John E. Hearst, Stephen T. Isaacs
-
Patent number: 5683661Abstract: A device comprising a light source, a sample holder and a temperature control chamber. The sample holder supports the vessels in a fixed relationship relative to the light source. The temperature control chamber surrounds the sample holder and vessels, so that a temperature control fluid may be passed around the sample vessels effectively maintaining the temperature of the sample vessels within a desired temperature range.Type: GrantFiled: June 7, 1995Date of Patent: November 4, 1997Assignee: Cerus CorporationInventors: David P. Hearst, George D. Cimino, John E. Hearst, Stephen T. Isaacs
-
Patent number: 5637759Abstract: Novel organic compounds and metal ion-containing amino acid chelates are described which are useful in solid phase synthesis of polypeptides and as magnetic resonance imaging (MRI) enhancing agents. The present invention also relates to a convenient and straightforward method to synthesize a metal-ligating amino acid suitable as MRI enhancing agents or for introducing a strong metal binding site at any chosen position in a peptide. Some compounds are designed to be compatible with N-.alpha.-Fmoc peptide synthesis strategy, and can easily be prepared on large scale. Thus, flexible linkers of different lengths and containing various structures can be placed between the .alpha.-carbon backbone of peptides and metal binding moieties. These peptides will provide a variety of affinity cleaving reagents which can be directed against protein or nucleic acid targets. Therefore, these molecules can serve as an important tool to study protein folding, protein-protein and protein-nucleic acid interactions.Type: GrantFiled: July 30, 1992Date of Patent: June 10, 1997Assignee: The Regents of the University of CaliforniaInventors: John E. Hearst, Tariq M. Rana, Matt Ban
-
Patent number: 5532145Abstract: Method useful for solving the problem of contamination of protein with nucleic acid. Rendering amplifiable contaminating nucleic acid in enzyme preparations substantially unamplifiable prior to use of the enzyme.Type: GrantFiled: November 20, 1992Date of Patent: July 2, 1996Assignee: Steritech, Inc.Inventors: John W. Tessman, George D. Cimino, Stephen T. Isaacs, John E. Hearst
-
Patent number: 5503721Abstract: A method for activating photoreactive compounds by supporting sample vessels containing a photoreactive compound at a selected temperature and irradiating the sample vessels while holding the sample vessels at a fixed relationship with the irradiating source so as to uniformly irradiate the compound.Type: GrantFiled: October 7, 1994Date of Patent: April 2, 1996Assignee: HRI Research, Inc.Inventors: David P. Hearst, George D. Cimino, John E. Hearst, Stephen T. Isaacs
-
Patent number: 5284940Abstract: Methods and compounds for the preparation of nucleic acid samples. Polymerase inhibitors are treated so as to allow for amplification of nucleic acid from biological sources, including whole blood.Type: GrantFiled: November 14, 1990Date of Patent: February 8, 1994Assignee: HRI Research, Inc.Inventors: Lily Lin, Stephen T. Isaacs, John E. Hearst
-
Patent number: 5221608Abstract: Method for treating nucleic acid that is to be amplified such that the nucleic acid is, after amplification, subsequently unamplifiable. Nucleic acid amplification is performed in a reaction containing means in the presence of an isopsoralen. The reaction is thereafter irradiated to render the amplified nucleic acid substantially unamplifiable.Type: GrantFiled: October 26, 1989Date of Patent: June 22, 1993Inventors: George D. Cimino, John E. Hearst, Stephen T. Isaacs, Kenneth C. Metchette, John W. Tessman
-
Patent number: 5184020Abstract: A device comprising a light source, a sample holder and a temperature control chamber. The sample holder supports the vessels in a fixed relationship relative to the light source. The temperature control chamber surrounds the sample holder and vessels, so that a temperature control fluid may be passed around the sample vessels effectively maintaining the temperature of the sample vessels within a desired temperature range.Type: GrantFiled: October 26, 1989Date of Patent: February 2, 1993Inventors: David P. Hearst, George D. Cimino, John E. Hearst, Stephen T. Isaacs
-
Patent number: 4398031Abstract: Two species of a coumarin derivative are disclosed, both of which may be produced from a 7-hydroxycoumarin precursor. The one species is an oxime and the other is a .beta.-haloallyl ester.A method for making a psoralen compound in high yield comprises treating these coumarin derivatives with an acid to fuse a furan ring thereto, and recovering a 5'-methyl psoralen therefrom. The 5'-methyl psoralen may be produced in up to about 70% overall yield with respect to the 7-hydroxycoumarin precursor.Type: GrantFiled: March 9, 1982Date of Patent: August 9, 1983Assignee: The Regents of the University of CaliforniaInventors: Dean R. Bender, John E. Hearst, Henry Rapoport
-
Patent number: 4196281Abstract: New psoralen compounds have been synthesized. The compounds all include the addition of substituent groups at the 4' position on the basic trioxsalen structure. Specifically, the compounds have the structure: ##STR1## wherein X may be any desired substituent such as halogenated alkyls, alcohols, ethers, aminoalkyls, etc. The new substituted psoralens exhibit high solubility in aqueous solution and low dissociation constants from deoxyribonucleic acid (DNA), as well as a reactivity with ribonucleic acids (RNA). The psoralen-DNA and psoralen-RNA adducts are useful as a substrate for studying the secondary structures of nucleic acids.Type: GrantFiled: August 31, 1978Date of Patent: April 1, 1980Assignee: Regents of the University of CaliforniaInventors: John E. Hearst, Henry Rapoport, Stephen Isaacs, Che-Kun J. Shen
-
Patent number: 4169204Abstract: New psoralen compounds have been synthesized. The compounds all include the addition of substituent groups at the 4'-position on the basic trioxsalen structure. Specifically, the compounds have the structure ##STR1## wherein ##STR2## where R is a mono or dicyclic radical which can contain one additional hetero atom in the nitrogen containing ring.The new substituted psoralens exhibit high solubility in aqueous solution and low dissociation constants from deoxyribonucleic acid (DNA), as well as a reactivity with ribonucleic acids (RNA).Type: GrantFiled: August 28, 1978Date of Patent: September 25, 1979Assignee: Regents of the University of CaliforniaInventors: John E. Hearst, Henry Rapoport, Stephen Isaacs, Che-Kun J. Shen
-
Patent number: 4124598Abstract: New psoralen compounds have been synthesized. The compounds all include the addition of substituent groups at the 4' position on the basic trioxsalen structure. Specifically, the compounds have the structure: ##STR1## wherein X may be any desired substituent such as halogenated alkyls, alcohols, ethers, aminoalkyls, etc. The new substituted psoralens exhibit high solubility in aqueous solution and low dissociation constants from deoxyribonucleic acid (DNA), as well as a reactivity with ribonucleic acids (RNA). Such psoralen compounds find use in the study of secondary structures of nucleic acids; as inhibitors of RNA replication; in the inactivation of viruses; and in the photo chemotherapy of psoriasis.Type: GrantFiled: October 20, 1976Date of Patent: November 7, 1978Assignee: Hoffmann-La Roche Inc.Inventors: John E. Hearst, Henry Rapoport, Stephen Isaacs, Che-Kun J. Shen